This procedural ruling keeps the case alive but does not establish liability or damages. Monitor for discovery milestones and any settlement discussions. The 10X Genomics settlement sublicense and Quanterix correspondence are key factual disputes that could drive materiality if the case proceeds to summary judgment or trial.
Price Chart
Executive Summary
The court granted Brandeis University leave to file a Second Amended Complaint against Bio-Rad, allowing new allegations that Bio-Rad failed to notify Brandeis about Quanterix's infringement of licensed patents for ~7.5 years, potentially depriving Brandeis of ~1.5 years of patent damages. Bio-Rad's motion to dismiss was denied as moot. This is an early-stage procedural ruling (motion for leave to amend) that keeps the case alive but does not resolve any liability or damages — a modest negative for Bio-Rad as litigation risk persists, but the financial exposure remains unquantified and the ruling is not a merits determination.
Court Ruling Details
Key Facts
- Court granted Brandeis University's motion to file a Second Amended Complaint against Bio-Rad.
- New allegations include Bio-Rad's failure to notify Brandeis of Quanterix's infringement of licensed patents for approximately 7.5 years.
- Alleged delay may have deprived Brandeis of ~1.5 years of patent damages (statutory 6-year lookback limit).
- Bio-Rad's motion to dismiss was denied as moot; the case continues.
- No damages have been awarded or quantified in this ruling — it is a procedural order on pleading amendments.
- The underlying license agreement covers patents related to droplet-based digital PCR technology, a core area for Bio-Rad.
Financial Impact
No damages awarded or quantified in this ruling. Potential exposure from royalty underpayments, settlement proceeds from 10X Genomics dispute, and Chapter 93A claims remains unquantified in the document.
Risk Factors
- Adverse judgment on breach of contract and Chapter 93A claims could result in damages including unpaid royalties, settlement proceeds from 10X Genomics, and potential treble damages under Massachusetts law.
- Litigation overhang may distract management and create uncertainty around Bio-Rad's IP licensing practices and digital PCR product line.
- Discovery could reveal additional instances of non-compliance or expand the scope of alleged breaches.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion from CourtListener.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-abc9bd02d2-BIO |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | Court Ruling | $368.75 $382.41 | ▼ −3.70% | ▼ −4.20% | $369.14 (−0.11%) |
Jun 12, 2026 16w ago | Institutional Cluster | $285.94 $282.44 | ▼ −1.22% | ▼ −1.90% | $369.14 (+29.10%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access